Core Insights - The new national basic medical insurance drug list and the first commercial health insurance innovative drug list were implemented in Beijing on January 1, including 114 new drugs in the basic insurance and 19 innovative drugs in the commercial insurance [1][2] Group 1: National Basic Medical Insurance Drug List - The updated national medical insurance directory includes a total of 3,253 drugs, with 114 new additions covering critical areas such as cancer, chronic diseases, and rare diseases [1] - New drugs include treatments for triple-negative breast cancer and rare diseases like Langerhans cell histiocytosis [1] Group 2: Commercial Health Insurance Drug List - The commercial insurance list includes 19 innovative drugs that are not covered by the basic medical insurance, requiring voluntary purchase by insured individuals [1] - The commercial insurance aims to supplement basic insurance by including high-innovation, clinically valuable drugs that significantly benefit patients, such as CAR-T cell immunotherapy products and treatments for Alzheimer's disease [1] Group 3: Patient Impact - An 8-year-old boy with high-risk neuroblastoma became one of the first beneficiaries of the new policy, significantly reducing his treatment costs from tens of thousands of yuan annually to a manageable amount through commercial insurance [2] - The inclusion of two immunotherapy drugs in the commercial insurance list provides families with financial relief and allows clinicians to confidently choose the most effective treatment options [2] Group 4: Expanded Coverage - The reimbursement scope for outpatient special diseases has been expanded, adding new treatment drugs for conditions like retinal disease and severe asthma, further alleviating patient financial burdens [2] - A 6-month transition period has been established for drugs removed from the previous national medical insurance directory, allowing continued reimbursement until June 30, 2026 [2]